Romatoid Artritte Tofasitinib ve Biyolojik DMARD (Hastalığı Modifiye Edici Anti-romatizmal İlaçların) Kesilme Oranlarının Karşılaştırılması: Sistematik Bir Derleme ve Bayes Network Meta-Analizi Regresyonu
Clin Exp Rheumatol 2017;35:689–99
Based on a Bayesian network meta-analysis (NMA) in patients with RA who previously showed failure with csDMARDs or biologics, discontinuation rates between tofacitinib (TOF) and biologics (TNFis, abatacept [ABT], rituximab [RTX] and tocilizumab [TCZ]) differed based on previous treatments and reasons for discontinuation.Data were collected from randomised controlled trials (RCT) found from literature searches from the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE. Disconti...